Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells

Drug Metabolism and Disposition

Volumn 32, Issue 12, 2004, Pages 1392-1401

  Brantley, Eileen ^a   Trapani, Valentina ^b,d   Alley, Michael C ^a   Hose, Curtis D ^c   Bradshaw, Tracey D ^b   Stevens, Malcolm F G ^b   Sausville, Edward A ^a,e   Stinson, Sherman F ^a,f  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c SAIC FREDERICK INC   (United States)

^d Depto di Biol Cell e Oncologia ^*  (Italy)

^e UNIVERSITY OF MARYLAND   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 3 METHYLPHENYL)BENZOTHIAZOLE; BENZOTHIAZOLE DERIVATIVE; CYTOCHROME P450 1A1; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOBLAST; CANCER CELL; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COVALENT BOND; DNA ADDUCT; DNA METABOLISM; DOSE RESPONSE; DRUG RECEPTOR BINDING; FLUORINATION; GENETIC ENGINEERING AND GENE TECHNOLOGY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MACROMOLECULE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; HUMANS; INDICATORS AND REAGENTS; MICROSOMES; NEOPLASMS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHODAMINES; RNA, MESSENGER; TETRAZOLIUM SALTS; THIAZOLES;

EID: 9444263203     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001057     Document Type: Article

References (39)

1. Akama T, Ishida H, Shida Y, Kimura U, Oomi K, Saito H, Fuse E, Kobayashi S, Yoda K, and Kasai H (1997) Design and synthesis of potent antitumor 5,4′-diaminoflavone derivatives based on metabolic considerations. J Med Chem 40:1894-1900.
2. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, and Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601.
3. Alley MC, Stinson SF, Pacula-Cox CM, Upadhyay KB, Bradshaw TD, Chua MS, Stevens MFG, and Sausville EA (2000) Pharmacologic evaluations of fluorinated 2-(4-amino phenyl) benzothiazole analogs with unique anti-cancer activities. Proc Am Assoc Cancer Res 41:813.
4. Bradshaw TD, Bibby MC, Double JA, Fichtner I, Cooper PA, Alley MC, Donohue S, Stinson SF, Tomaszewjski JE, Sausville EA, and Stevens MFG (2002a) Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 1:239-246.
5. Bradshaw TD, Chua MS, Browne HL, Trapani V, Sausville EA, and Stevens MFG (2002b) In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Br J Cancer 86:1348-1354.
6. Bradshaw TD, Shi DF, Schultz RJ, Paull KD, Kelland L, Wilson A, Garner C, Fiebig HH, Wrigley S, and Stevens MFG (1998a) Influence of 2-(4-aminophenyl) benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo. Br J Cancer 78:421-429.
7. Bradshaw TD, Stevens MFG, and Westwell AD (2001) The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds. Curr Med Chem 8:203-210.
8. Bradshaw TD, Wrigley S, Shi DF, Schultz RJ, Paull KD, and Stevens MFG (1998b) 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity. Br J Cancer 77:745-752.
9. Cain K (2003) Chemical-induced apoptosis: formation of the Apaf-1 apoptosome. Drug Metab Rev 35:337-363.
10. Chase M, Chung RY, and Chiocca EA (1998) An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 16:444-448.
11. Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, and Stevens MF (2000) Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60:5196-5203.
12. Chua MS, Shi DF, Wrigley S, Bradshaw TD, Hutchinson I, Shaw PN, Barrett DA, Stanley LA, and Stevens MFG (1999) Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl-)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines. J Med Chem 42:381-392.
13. Denison MS, Phelan D, Winter GM, and Ziccardi MH (1998) Carbaryl, a carbamate insecticide, is a ligand for the hepatic Ah (dioxin) receptor. Toxicol Appl Pharmacol 152:406-414.
14. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, and Chitambar CR (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18:767-773.
15. Hollingshead M, Alley MC, Kaur G, Pacula-Cox CM, and Stinson SF (2004) NCI specialized procedures in preclinical drug evaluations, in Cancer Drug Discovery and Development: Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval (Teicher BA and Andrews PA eds), pp 153-182, Humana Press, Inc., Totowa, NJ.
16. Hose CD, Hollingshead M, Sausville EA, and Monks A (2003) Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5- fluoro-benzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther 2:1265-1272.
17. Hutchinson I, Chua MS, Browne HL, Trapani V, Bradshaw TD, Westwell AD, and Stevens MF (2001) Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 44:1446-1455.
18. Hutchinson I, Jennings SA, Vishnuvajjala BR, Westwell AD, and Stevens MFG (2002) Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. J Med Chem 45:744-747.
19. Jain S, Dolwick KM, Schmidt JV, and Bradfield CA (1994) Potent transactivation domains of the Ah receptor and the Ah receptor nuclear translocator map to their carboxyl termini. J Biol Chem 269:31518-31524.
20. Jones BK, Monks BR, Liebhaber SA, and Cooke NE (1995) The human growth hormone gene is regulated by a multicomponent locus control region. Mol Cell Biol 15:7010-7021.
21. Jounaidi Y, Hecht JE, and Waxman DJ (1998) Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 58:4391-4401.
22. Kashiyama E, Hutchinson I, Chua MS, Stinson SF, Phillips LR, Kaur G, Sausville EA, Bradshaw TD, Westwell AD, and Stevens MF (1999) Antitumor benzothiazoles. 8. Synthesis, metabolic formation and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles. J Med Chem 42:4172-4184.
23. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, and Ames MM (2002) Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 62:143-153.
24. Lampen A, Bader A, Bestmann T, Winkler M, Witte L, and Borlak JT (1998) Catalytic activities, protein- and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. Xenobiotica 28:429-441.
25. Leong CO, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA, Double JA, Bradshaw TD, and Stevens MFG (2003) Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer 88:470-477.
26. Loaiza-Perez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MFG, Bradshaw TD, and Sausville EA (2002) Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3- methylphenyl)benzothiazole. Mol Pharmacol 61:13-19.
27. Monks A, Harris E, Hose C, Connelly J, and Sausville EA (2003) Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3- methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 63:766-772.
28. Monks A, Scudiero DA, Johnson GS, Paull KD, and Sausville EA (1997) The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des 12:533-541.
29. O'Brien SE, Browne HL, Bradshaw TD, Westwell AD, Stevens MF, and Laughton CA (2003) Antitumor benzothiazoles. Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl)benzothiazoles to reactive intermediates by cytochrome P4501 A1. Org Biomol Chem 1:493-497.
30. Pichard-Garcia L, Weaver RJ, Eckett N, Scarfe G, Fahre J-M, Lucas C, and Maurel P (2004) The Olivacine derivative S 16020 (9-hydroxy-5,6-dimethyl-N-[2- (dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-carboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture. Drug Metab Dispos 32:80-88.
31. Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, and Sausville EA (1999) Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem Pharmacol 57:1283-1295.
32. Rochat B, Morsman JM, Murray GI, Figg WD, and McLeod HL (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296:537-541.
33. Safe S and Krishnan V (1995) Cellular and molecular biology of aryl hydrocarbon (Ah) receptor-mediated gene expression. Arch Toxicol Suppl 17:99-115.
34. Shi DF, Bradshaw TD, Wrigley S, McCall CJ, Lelieveld P, Fichtner I, and Stevens MF (1996) Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl) benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem 39:3375-3384.
35. Sladek NE (1994) Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines, in Anticancer Drugs: Reactive Metabolism and Interactions (Powers G ed), pp 79-156, Pergamon Press, Oxford, UK.
36. Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF, Kenney S, Keller J, and Boyd MR (1992) Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 12:1035-1053.
37. Trapani V, Patel V, Leong CO, Ciolino HP, Yeh GC, Hose C, Trepel JB, Stevens MFG, Sausville EA, and Loaiza-Perez AI (2003) DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Br J Cancer 88:599-605.
38. Wells G, Bradshaw TD, Diana P, Seaton A, Shi DF, Westwell AD, and Stevens MFG (2000) Antitumour benzothiazoles. Part 10: the synthesis and antitumour activity of benzothiazole substituted quinol derivatives. Bioorg Med Chem Lett 10:513-515.
39. Whitlock JP Jr (1999) Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39: 103-125.